Status:
COMPLETED
Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane
Lead Sponsor:
Austin Health
Conditions:
Renal Dialysis
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to determine whether a novel haemodialysis membrane, compared with the standard dialysis membrane, will increase the removal of beta2-microglobulin in chronic dialysis pat...
Detailed Description
Despite advances in treatment of kidney diseases, morbidity and mortality of chronic dialysis patients remains unsatisfactory. Standard haemodialysis membranes remove middle-sized molecule solutes poo...
Eligibility Criteria
Inclusion
- Chronic haemodialysis patients for more than 2 years
- Urine output \<100 mL per day
- 3 haemodialysis sessions per week
- Permanent arteriovenous dialysis access
Exclusion
- Serum albumin \<25 g/L
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00824837
Start Date
October 1 2008
End Date
December 1 2008
Last Update
July 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Austin Health
Melbourne, Victoria, Australia, 3084